NASDAQ:ALDR - Alder Biopharmaceuticals Stock Price, News, & Analysis

Sign in or create an account to add this stock to your watchlist.
$11.01 -0.11 (-0.99 %)
(As of 05/24/2019 06:48 AM ET)
Previous Close$11.12
Today's Range$10.82 - $11.07
52-Week Range$9.44 - $20.87
Volume354,777 shs
Average Volume1.09 million shs
Market Capitalization$919.38 million
P/E RatioN/A
Dividend YieldN/A
Beta2.74
Alder BioPharmaceuticals, Inc. operates as a clinical-stage biopharmaceutical company. It discovers, develops, and commercializes therapeutic antibodies to transform the treatment paradigm for patients with migraine in the United States, Australia, and Ireland. The company's lead product candidate is eptinezumab, a monoclonal antibody (mAb) inhibiting calcitonin gene-related peptide, which is in the late-stage clinical development for the prevention of migraine. It also develops ALD1910, a preclinical mAb that inhibits pituitary adenylate cyclase-activating polypeptide-38 for migraine prevention; and Clazakizumab, a mAb inhibiting the pro-inflammatory cytokine interleukin-6 that has completed two Phase 2b clinical trials. The company has strategic collaboration with CSL Limited for the development of clazakizumab as a therapeutic option for solid organ transplant rejection. Alder BioPharmaceuticals, Inc. was incorporated in 2002 and is headquartered in Bothell, Washington.

Receive ALDR News and Ratings via Email

Sign-up to receive the latest news and ratings for ALDR and its competitors with MarketBeat's FREE daily newsletter.

Industry, Sector and Symbol

Industry Pharmaceutical preparations
Sub-IndustryN/A
SectorMedical
Current SymbolNASDAQ:ALDR
CUSIPN/A
Phone425-205-2900

Debt

Price-To-Earnings

Sales & Book Value

Annual Sales$1.62 million
Book Value$1.88 per share

Profitability

Net Income$-296,430,000.00

Miscellaneous

Employees202
Market Cap$919.38 million
Next Earnings Date8/6/2019 (Estimated)
OptionableOptionable

Alder Biopharmaceuticals (NASDAQ:ALDR) Frequently Asked Questions

What is Alder Biopharmaceuticals' stock symbol?

Alder Biopharmaceuticals trades on the NASDAQ under the ticker symbol "ALDR."

How were Alder Biopharmaceuticals' earnings last quarter?

Alder Biopharmaceuticals Inc (NASDAQ:ALDR) issued its quarterly earnings results on Thursday, May, 2nd. The biopharmaceutical company reported ($1.63) EPS for the quarter, missing the consensus estimate of ($1.16) by $0.47. View Alder Biopharmaceuticals' Earnings History.

When is Alder Biopharmaceuticals' next earnings date?

Alder Biopharmaceuticals is scheduled to release their next quarterly earnings announcement on Tuesday, August 6th 2019. View Earnings Estimates for Alder Biopharmaceuticals.

What price target have analysts set for ALDR?

11 analysts have issued 1-year price objectives for Alder Biopharmaceuticals' stock. Their forecasts range from $14.00 to $30.00. On average, they expect Alder Biopharmaceuticals' stock price to reach $21.20 in the next twelve months. This suggests a possible upside of 92.6% from the stock's current price. View Analyst Price Targets for Alder Biopharmaceuticals.

What is the consensus analysts' recommendation for Alder Biopharmaceuticals?

11 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Alder Biopharmaceuticals in the last year. There are currently 1 sell rating, 3 hold ratings and 7 buy ratings for the stock, resulting in a consensus recommendation of "Buy." View Analyst Ratings for Alder Biopharmaceuticals.

What are Wall Street analysts saying about Alder Biopharmaceuticals stock?

Here are some recent quotes from research analysts about Alder Biopharmaceuticals stock:
  • 1. According to Zacks Investment Research, "Alder Biopharmaceuticals Inc. is a clinical-stage biopharmaceutical company. It discovers, develops and seeks to commercialize therapeutic antibodies. It is developing monoclonal antibodies comprising ALD403, for the prevention of migraine; and Clazakizumab, in the treatment of rheumatoid arthritis and psoriatic arthritis. Alder Biopharmaceuticals Inc. is headquartered in Bothell, Washington. " (5/7/2019)
  • 2. Mizuho analysts commented, "We maintain our Neutral rating on the shares as we see limited catalysts for the shares prior to FDA approval; financing overhang as well as risks associated with commercial launch." (5/3/2019)
  • 3. Cantor Fitzgerald analysts commented, ". We reiterate our Neutral rating and $14 PT on ALDR. Today (5/2), Alder reported 1Q19 earnings, including cash and STI, of $498.5M. With the BLA submission of eptinezumab (epti’) accepted by the FDA and with a PDUFA date set for February 2020, the company expects to launch the drug by early next year (1Q20), and we believe its cash on hand will enable it to fund building out a right-sized" neurology/headache-specialist focused sales force, as well as other launch prep this year; it started with the recent hiring of a chief commercial officer." (5/2/2019)

Has Alder Biopharmaceuticals been receiving favorable news coverage?

Press coverage about ALDR stock has been trending negative recently, according to InfoTrie. The research group identifies negative and positive media coverage by analyzing more than six thousand blog and news sources. The firm ranks coverage of publicly-traded companies on a scale of -5 to 5, with scores closest to five being the most favorable. Alder Biopharmaceuticals earned a media sentiment score of -2.7 on InfoTrie's scale. They also gave headlines about the biopharmaceutical company a news buzz of 5.0 out of 10, meaning that recent media coverage is somewhat likely to have an impact on the company's share price in the immediate future.

Who are some of Alder Biopharmaceuticals' key competitors?

What other stocks do shareholders of Alder Biopharmaceuticals own?

Based on aggregate information from My MarketBeat watchlists, some companies that other Alder Biopharmaceuticals investors own include NVIDIA (NVDA), Celator Pharmaceuticals (CPXX), Alibaba Group (BABA), Celgene (CELG), TherapeuticsMD (TXMD), Gilead Sciences (GILD), Synergy Pharmaceuticals (SGYP), Sarepta Therapeutics (SRPT), AbbVie (ABBV) and Celldex Therapeutics (CLDX).

Who are Alder Biopharmaceuticals' key executives?

Alder Biopharmaceuticals' management team includes the folowing people:
  • Dr. John A. Latham, Co-Founder & Chief Scientific Officer (Age 59)
  • Mr. Larry K. Benedict, Principal Accounting Officer & Exec. VP (Age 58)
  • Dr. Jeffrey T. L. Smith, Managing Director of Alder Biopharmaceuticals Limited (Age 59)
  • Mr. Robert W. Azelby, Pres, CEO & Director (Age 51)
  • Mr. Carlos Campoy, Chief Financial Officer

Who are Alder Biopharmaceuticals' major shareholders?

Alder Biopharmaceuticals' stock is owned by a number of of institutional and retail investors. Top institutional shareholders include Goldman Sachs Group Inc. (3.94%), Pinnacle Associates Ltd. (1.10%), Geode Capital Management LLC (1.04%), Northern Trust Corp (0.90%), Charles Schwab Investment Management Inc. (0.46%) and Schonfeld Strategic Advisors LLC (0.30%). Company insiders that own Alder Biopharmaceuticals stock include Erin Lavelle, James B Bucher, Jeffrey T L Smith, John A Latham, Mark James Litton and Stephen M Dow. View Institutional Ownership Trends for Alder Biopharmaceuticals.

Which major investors are selling Alder Biopharmaceuticals stock?

ALDR stock was sold by a variety of institutional investors in the last quarter, including Wells Fargo & Company MN, Goldman Sachs Group Inc., Citigroup Inc., Schonfeld Strategic Advisors LLC, JPMorgan Chase & Co., Pinnacle Associates Ltd., New York State Common Retirement Fund and California Public Employees Retirement System. Company insiders that have sold Alder Biopharmaceuticals company stock in the last year include Erin Lavelle, James B Bucher, Jeffrey T L Smith, John A Latham and Mark James Litton. View Insider Buying and Selling for Alder Biopharmaceuticals.

Which major investors are buying Alder Biopharmaceuticals stock?

ALDR stock was bought by a variety of institutional investors in the last quarter, including Geode Capital Management LLC, Neuberger Berman Group LLC, Charles Schwab Investment Management Inc., Fosun International Ltd, Northern Trust Corp, Jacobs Levy Equity Management Inc., Metropolitan Life Insurance Co NY and FNY Investment Advisers LLC. View Insider Buying and Selling for Alder Biopharmaceuticals.

How do I buy shares of Alder Biopharmaceuticals?

Shares of ALDR can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.

What is Alder Biopharmaceuticals' stock price today?

One share of ALDR stock can currently be purchased for approximately $11.01.

How big of a company is Alder Biopharmaceuticals?

Alder Biopharmaceuticals has a market capitalization of $919.38 million and generates $1.62 million in revenue each year. The biopharmaceutical company earns $-296,430,000.00 in net income (profit) each year or ($4.87) on an earnings per share basis. Alder Biopharmaceuticals employs 202 workers across the globe.

What is Alder Biopharmaceuticals' official website?

The official website for Alder Biopharmaceuticals is http://www.alderbio.com/.

How can I contact Alder Biopharmaceuticals?

Alder Biopharmaceuticals' mailing address is 11804 NORTH CREEK PARKWAY SOUTH, BOTHELL WA, 98011. The biopharmaceutical company can be reached via phone at 425-205-2900 or via email at [email protected]


MarketBeat Community Rating for Alder Biopharmaceuticals (NASDAQ ALDR)

Community Ranking:  2.8 out of 5 (star star)
Outperform Votes:  363 (Vote Outperform)
Underperform Votes:  282 (Vote Underperform)
Total Votes:  645
MarketBeat's community ratings are surveys of what our community members think about Alder Biopharmaceuticals and other stocks. Vote "Outperform" if you believe ALDR will outperform the S&P 500 over the long term. Vote "Underperform" if you believe ALDR will underperform the S&P 500 over the long term. You may vote once every thirty days.
This page was last updated on 5/24/2019 by MarketBeat.com Staff

Featured Article: Balanced Fund

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.

Yahoo Gemini Pixel